The November 2026 update means no Roundup settlement money is available yet for claims linking the glyphosate-based weedkiller to non-Hodgkin lymphoma. The proposed $7.25 billion class deal still needs final court approval, while a Supreme Court ruling has narrowed failure-to-warn claims.
Non-Hodgkin lymphoma is a cancer of the lymph system. The November picture is therefore wait-and-watch, not file-and-get-paid. Readers should follow the Missouri court decision and keep exposure and medical records in order.
Official resources:
- Read the official notice from Cornell — Use this primary source to verify the official announcement.
- Explore the official data from Uscourts — Use this primary source to review the underlying data.
Table of Contents
- Is any settlement money available now?
- How would the $7.25 billion plan work?
- How did the Supreme Court narrow warning claims?
- What do the latest trial and case counts signal?
Is any settlement money available now?
TortAdvisor reported in its November 6 update that the class won preliminary approval March 4, 2026. A fairness hearing followed Sept. 14, 2026 before Judge Timothy Boyer in St. Louis.
No final-approval order or payments were reported as of Nov. 6, 2026. Bayer CEO Bill Anderson told Reuters, republished by SRN News in its November 3 report, that he expects Missouri approval before Christmas. He said it could come any week now. Treat that as a forecast to watch, not proof money is ready.
How would the $7.25 billion plan work?
Monsanto announced in the Bayer media announcement on Feb. 17, 2026 a proposed nationwide class settlement of up to $7.25 billion. Payments would come as declining capped annual amounts for up to 21 years after court approval.
📨 Get Free Mass Tort Guides Alerts
Free · No spam · Unsubscribe anytime
That structure spreads cost over time. Bayer's Quarterly Statement Q3 2026 Legal Risks describes the plan as a long-term claims program for current and future non-Hodgkin lymphoma claims. It is not a round of one-time checks. Future claimants would file into the same program if the court approves it.
How did the Supreme Court narrow warning claims?
The U.S. Supreme Court held in the Cornell LII syllabus that its 7-2 decision in Monsanto v. Durnell came June 25, 2026. The Court said FIFRA, the federal pesticide-labeling law, expressly preempts state failure-to-warn claims.
Preemption here means federal law blocks a state demand for a cancer warning that EPA left off an approved Roundup label. A failure-to-warn claim argues the maker should have warned about risk. A Holland & Knight alert on June 26, 2026 said the ruling reversed a $1.25 million Missouri verdict against Monsanto. The firm said the decision could limit failure-to-warn liability in pending state cases nationwide. That raises the bar for warning-based cases going forward.
What do the latest trial and case counts signal?
Insurance Journal, republishing Reuters reporting by Dietrich Knauth on Oct. 30, 2026, said a unanimous St. Louis jury ruled for Monsanto Oct. 29, 2026. The case involved three women alleging Roundup caused non-Hodgkin lymphoma.
It was the first trial after the Supreme Court ruling. The Judicial Panel on Multidistrict Litigation counted 916 pending actions in MDL 2741 in its Nov. 2, 2026 report. MDL means many similar federal cases are grouped for pretrial handling. The docket stays large, but it is shrinking as settlements and rulings narrow active claims. What readers can do now is limited and concrete: Talk to a licensed attorney about deadlines before you act on opt-out or claim choices.
- Watch for the Missouri final-approval order, not payout ads or call centers.
- List purchase, work, and exposure dates with product names if known.
- Keep diagnosis records and treatment dates together for later review.
You Might Also Like
- Monsanto Roundup Lawsuit: Liability Theories Behind the October Settlement
- Monsanto Roundup Settlement: Who Qualifies for the Latest Payout?
- Johnson & Johnson Talcum Powder Lawsuit: What the 2026 Update Changes